PE20090493A1 - DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA - Google Patents
DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICAInfo
- Publication number
- PE20090493A1 PE20090493A1 PE2008001220A PE2008001220A PE20090493A1 PE 20090493 A1 PE20090493 A1 PE 20090493A1 PE 2008001220 A PE2008001220 A PE 2008001220A PE 2008001220 A PE2008001220 A PE 2008001220A PE 20090493 A1 PE20090493 A1 PE 20090493A1
- Authority
- PE
- Peru
- Prior art keywords
- pyridazin
- pyridazine
- alkylene
- alkyl
- imidazo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
REFERIDA A COMPUESTOS DERIVADOS DE 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA DE FORMULA (I) DONDE R2 ES ARILO OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALQUILO(C1-C6), ALQUIL(C1-C6)-TIO, -CN, ENTRE OTROS; A ES ALQUILENO(C1-C7) OPCIONALMENTE SUSTITUIDO CON Ra; B ES ALQUILENO(C1-C7) OPCIONALMENTE SUSTITUIDO CON Rb; L ES N OPCIONALMENTE SUSTITUIDO CON UN Rc O Rd, O ES C SUSTITUIDO CON UN Re1 Y UN Rd, ENTRE OTROS, DONDE DOS GRUPOS Ra PUEDEN FORMAR UN ALQUILENO(C1-C6), Ra Y Rb PUEDEN FORMAR UN ENLACE O UN ALQUILENO(C1-C6), Ra Y Rc PUEDEN FORMAR UN ENLACE O UN ALQUILENO(C1-C6), Rb Y Rc PUEDEN FORMAR UN ENLACE O UN ALQUILENO(C1-C6); Rd ES H, ALQUILO(C1-C6), HIDROXI-ALQUILO(C1-C6), FLUOROALQUILO(C1-C6), ENTRE OTROS, Re1 ES -NR4R5, ENTRE OTROS, EN DONDE R4 Y R5 SON CADA UNO H, ALQUILO(C1-C6), CICLOALQUILO(C3-C7), ENTRE OTROS; R7 Y R8 SON CADA UNO H O ALQUILO(C1-C6). SON COMPUESTOS PREFERIDOS: 2-(4-FLUORO-FENIL)-6-PIPERAZIN-1-IL-3-PIRIDAZIN-4-IL-IMIDAZO[1,2-b]PIRIDAZINA, 2-(4-FLUORO-FENIL)-6-((R)-3-METIL-PIPERAZIN-1-IL)-3-PIRIDAZIN-4-IL-IMIDAZO[1,2-b]PIRIDAZINA, 6-(3,3-DIMETIL-PIPERAZIN-1-IL)-2-(4-FLUORO-FENIL)-3-PIRIDAZIN-4-IL-IMIDAZO[1,2-b]PIRIDAZINA, ENTRE OTROS. SE REFIERE TAMBIEN UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA FOSFORILACION DE LA CASEINA POR LAS CASEINA CINASAS 1 EPSILON Y DELTA SIENDO UTILES EN EL TRATAMIENTO DEL INSOMNIO PRIMARIO, SOMNOLENCIA EXCESIVA, TRASTORNOS DE ANSIEDAD
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95071107P | 2007-07-19 | 2007-07-19 | |
FR0705224A FR2918986B1 (fr) | 2007-07-19 | 2007-07-19 | Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20090493A1 true PE20090493A1 (es) | 2009-05-27 |
Family
ID=39183122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008001220A PE20090493A1 (es) | 2007-07-19 | 2008-07-17 | DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA |
Country Status (22)
Country | Link |
---|---|
US (2) | US8455491B2 (es) |
EP (1) | EP2178879B1 (es) |
JP (1) | JP5431319B2 (es) |
KR (1) | KR20100041771A (es) |
CN (1) | CN101784552A (es) |
AR (1) | AR069272A1 (es) |
AU (1) | AU2008300449A1 (es) |
BR (1) | BRPI0814510A2 (es) |
CA (1) | CA2693116A1 (es) |
CL (1) | CL2008002138A1 (es) |
CO (1) | CO6290690A2 (es) |
EA (1) | EA016376B1 (es) |
ES (1) | ES2429765T3 (es) |
FR (1) | FR2918986B1 (es) |
MA (1) | MA31616B1 (es) |
NZ (1) | NZ582683A (es) |
PA (1) | PA8789901A1 (es) |
PE (1) | PE20090493A1 (es) |
TW (1) | TW200914456A (es) |
UY (1) | UY31236A1 (es) |
WO (1) | WO2009037394A2 (es) |
ZA (1) | ZA201001214B (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
WO2009014910A2 (en) | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders |
US7868001B2 (en) * | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
FR2939134A1 (fr) * | 2008-12-01 | 2010-06-04 | Sanofi Aventis | Derives de 6-cycloamino-3-(1h-pyrrolo°2,3-b!pyridin-4-yl) imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique |
FR2940285A1 (fr) | 2008-12-19 | 2010-06-25 | Sanofi Aventis | Derives de 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo °1,2-b!-pyridazine et 6-cycloamino-2-furanyl-3- (pyridin-4-yl)imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique |
FR2940284B1 (fr) * | 2008-12-19 | 2011-02-18 | Sanofi Aventis | Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique |
ES2497566T3 (es) | 2009-10-01 | 2014-09-23 | Cymabay Therapeutics, Inc. | Sales de tetrazol-1-il-fenoximetil-tiazol-2-il-piperidinil-pirimidina sustituida |
KR20120105449A (ko) * | 2009-10-23 | 2012-09-25 | 얀센 파마슈티카 엔.브이. | 오렉신 수용체 조절제로서의 이치환된 옥타하이드로피롤로[3,4-c]피롤 |
WO2011050202A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
EP2491034B1 (en) | 2009-10-23 | 2013-12-18 | Janssen Pharmaceutica, N.V. | Fused heterocyclic compounds as orexin receptor modulators |
US20120220581A1 (en) | 2009-10-30 | 2012-08-30 | Janssen-Cilag, S.A. | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS |
AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
WO2011163090A1 (en) | 2010-06-23 | 2011-12-29 | Metabolex, Inc. | Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
JP5181156B2 (ja) | 2010-08-09 | 2013-04-10 | 株式会社ファルマデザイン | カゼインキナーゼ1δ及びカゼインキナーゼ1ε阻害剤 |
WO2012080727A2 (en) | 2010-12-14 | 2012-06-21 | Electrophoretics Limited | Casein kinase 1delta (ck1delta) inhibitors |
US9586962B2 (en) | 2011-04-20 | 2017-03-07 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators |
WO2013000924A1 (en) | 2011-06-27 | 2013-01-03 | Janssen Pharmaceutica Nv | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES |
CA2872216C (en) | 2012-06-26 | 2021-07-20 | Janssen Pharmaceutica Nv | Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders |
JP6174695B2 (ja) | 2012-07-09 | 2017-08-02 | ヤンセン ファーマシューティカ エヌ.ベー. | ホスホジエステラーゼ10酵素の阻害剤 |
US9556179B2 (en) | 2012-12-21 | 2017-01-31 | Bristol-Myers Squibb Company | Substituted imidazoles as casein kinase 1 D/E inhibitors |
CN104837844B (zh) * | 2012-12-21 | 2017-08-29 | 百时美施贵宝公司 | 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪 |
GB201321734D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
ES2728932T3 (es) * | 2014-01-09 | 2019-10-29 | Intra Cellular Therapies Inc | Compuestos orgánicos |
CA2960253A1 (en) | 2016-03-10 | 2017-09-10 | Janssen Pharmaceutica Nv | Methods of treating depression using orexin-2 receptor antagonists |
AU2017305392A1 (en) | 2016-08-03 | 2019-02-21 | Cymabay Therapeutics, Inc. | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
DK3483164T3 (da) | 2017-03-20 | 2020-03-23 | Forma Therapeutics Inc | Pyrrolopyrrolsammensætninger som pyruvatkinase (pkr) aktivatorer |
CA3090385A1 (en) | 2018-02-05 | 2019-08-08 | Alkermes, Inc. | Compounds for the treatment of pain |
US20230055923A1 (en) | 2018-09-19 | 2023-02-23 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
US20220031671A1 (en) | 2018-09-19 | 2022-02-03 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
TW202112368A (zh) | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
US20230192699A1 (en) * | 2020-03-27 | 2023-06-22 | Gritscience Biopharmaceuticals Co., Ltd. | Compounds as casein kinase inhibitors |
CN115335057A (zh) * | 2020-03-27 | 2022-11-11 | 北京原基华毅生物科技有限公司 | 抑制酪蛋白激酶的方法 |
AU2022367432A1 (en) | 2021-10-14 | 2024-05-02 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989001333A1 (en) * | 1987-08-07 | 1989-02-23 | The Australian National University | IMIDAZO[1,2-b]PYRIDAZINES |
IL146729A0 (en) | 1999-06-08 | 2002-07-25 | Aventis Pharma Inc | Screening methods for altering circadian rhythm proteins |
DE602004020685D1 (de) * | 2003-12-11 | 2009-05-28 | Aventis Pharma Inc | Substituierte 1h-pyrroloä3,2-b, 3,2-c und 2,3-cüpyridin-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i-epsilon |
US20090023737A1 (en) * | 2004-02-12 | 2009-01-22 | Neurogen Corporation | Imidazo-Pyridazines, Triazolo-Pyridazines and Related Benzodiazepine Receptor Ligands |
GB0515026D0 (en) * | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
EP1910369A1 (en) * | 2005-07-29 | 2008-04-16 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
DE102005042742A1 (de) * | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
-
2007
- 2007-07-19 FR FR0705224A patent/FR2918986B1/fr active Active
-
2008
- 2008-07-15 PA PA20088789901A patent/PA8789901A1/es unknown
- 2008-07-17 PE PE2008001220A patent/PE20090493A1/es not_active Application Discontinuation
- 2008-07-17 UY UY31236A patent/UY31236A1/es not_active Application Discontinuation
- 2008-07-17 TW TW097127189A patent/TW200914456A/zh unknown
- 2008-07-18 JP JP2010516539A patent/JP5431319B2/ja not_active Expired - Fee Related
- 2008-07-18 KR KR1020107001087A patent/KR20100041771A/ko not_active Application Discontinuation
- 2008-07-18 WO PCT/FR2008/001057 patent/WO2009037394A2/fr active Application Filing
- 2008-07-18 EA EA201070161A patent/EA016376B1/ru not_active IP Right Cessation
- 2008-07-18 CN CN200880103986A patent/CN101784552A/zh active Pending
- 2008-07-18 ES ES08831515T patent/ES2429765T3/es active Active
- 2008-07-18 AR ARP080103097A patent/AR069272A1/es unknown
- 2008-07-18 CL CL2008002138A patent/CL2008002138A1/es unknown
- 2008-07-18 AU AU2008300449A patent/AU2008300449A1/en not_active Abandoned
- 2008-07-18 NZ NZ582683A patent/NZ582683A/en not_active IP Right Cessation
- 2008-07-18 BR BRPI0814510-5A2A patent/BRPI0814510A2/pt not_active IP Right Cessation
- 2008-07-18 CA CA2693116A patent/CA2693116A1/fr not_active Abandoned
- 2008-07-18 EP EP08831515.5A patent/EP2178879B1/fr active Active
-
2010
- 2010-01-11 US US12/685,030 patent/US8455491B2/en not_active Expired - Fee Related
- 2010-01-19 CO CO10004823A patent/CO6290690A2/es not_active Application Discontinuation
- 2010-02-17 MA MA32629A patent/MA31616B1/fr unknown
- 2010-02-19 ZA ZA2010/01214A patent/ZA201001214B/en unknown
-
2013
- 2013-05-06 US US13/887,845 patent/US9108971B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2009037394A3 (fr) | 2009-06-18 |
EA201070161A1 (ru) | 2010-08-30 |
ES2429765T3 (es) | 2013-11-15 |
CN101784552A (zh) | 2010-07-21 |
JP5431319B2 (ja) | 2014-03-05 |
US8455491B2 (en) | 2013-06-04 |
BRPI0814510A2 (pt) | 2015-02-03 |
CL2008002138A1 (es) | 2009-10-23 |
JP2010533686A (ja) | 2010-10-28 |
PA8789901A1 (es) | 2009-02-09 |
CO6290690A2 (es) | 2011-06-20 |
FR2918986A1 (fr) | 2009-01-23 |
AR069272A1 (es) | 2010-01-13 |
US9108971B2 (en) | 2015-08-18 |
NZ582683A (en) | 2011-07-29 |
KR20100041771A (ko) | 2010-04-22 |
US20100152157A1 (en) | 2010-06-17 |
TW200914456A (en) | 2009-04-01 |
ZA201001214B (en) | 2011-05-25 |
AU2008300449A1 (en) | 2009-03-26 |
CA2693116A1 (fr) | 2009-03-26 |
EP2178879B1 (fr) | 2013-07-03 |
EA016376B1 (ru) | 2012-04-30 |
MA31616B1 (fr) | 2010-08-02 |
UY31236A1 (es) | 2009-03-02 |
EP2178879A2 (fr) | 2010-04-28 |
US20130245023A1 (en) | 2013-09-19 |
WO2009037394A2 (fr) | 2009-03-26 |
FR2918986B1 (fr) | 2009-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20090493A1 (es) | DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
PE20090556A1 (es) | DERIVADOS DE 6-CICLOAMINO-3-(PIRIDIN-4-IL) IMIDAZO [1,2-b]-PIRIDAZINA COMO INHIBIDORES DE CASEINA QUINASAS Y SU PREPARACION | |
PE20190336A1 (es) | Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
PE20150218A1 (es) | Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
PE20090506A1 (es) | DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4 | |
PE20110545A1 (es) | Compuestos de triazolopiridina como inhibidores de jak | |
PE20130012A1 (es) | Derivados de pirazol como inhibidores de jak | |
AR074052A1 (es) | Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa | |
PE20110572A1 (es) | DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO INHIBIDORES DE MET | |
AR053728A1 (es) | Pirimidinas condensadas como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia y composiciones farmaceuticas que las contienen en combinacion con otros agentes terapeuticos | |
EA023824B1 (ru) | ПРОИЗВОДНЫЕ 3,4-ДИГИДРОПИРРОЛО[1,2-a]ПИРАЗИН-1-ИЛАМИНА, ПРИГОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (BACE) | |
PE20090370A1 (es) | Derivados de heterociclo fusionado como inhibidores de quinasa | |
JP2016509583A (ja) | キナーゼ調節のための化合物および方法、ならびにその適応 | |
PE20140390A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
PE20161246A1 (es) | Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo | |
PE20151249A1 (es) | Derivados de pirazolopirimidina como inhibidores de jak quinasas | |
PE20080893A1 (es) | Triazoles biciclicos como moduladores de la proteina cinasa | |
PE20130611A1 (es) | Triazolopiridinas sustituidas | |
HRP20192197T2 (hr) | Derivati karbazola | |
AR093077A1 (es) | ANTAGONISTAS DE mGlu2/3 PARA EL TRATAMIENTO DE LOS TRASTORNOS AUTISTAS | |
PE20120534A1 (es) | PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt | |
PE20090651A1 (es) | Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3 | |
PE20110560A1 (es) | NUEVOS DERIVADOS DE TRIAZOLO[4,3-a]PIRIDINA, SU PROCEDIMIENTO DE PREPARACION, SU APLICACION COMO MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS Y NUEVA UTILIZACION PARTICULARMENTE COMO INHIBIDORES DE MET | |
JP2012522759A (ja) | イミダゾ[2,1−b][1,3,4]チアジアゾール誘導体 | |
PE20090960A1 (es) | Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |